Use of inhibitors of the activator protein 1 (AP-1) for preventing adhesions
Aspects of the present disclosure include methods of treating a subject to reduce adhesion formation.
1 . A method of treating a subject to reduce adhesion formation or to reduce already-formed adhesions, the method comprising:
administering topically to abdominal cavity of an abdominal surgery patient thereof an effective dose of a small molecule inhibitor of the Activator Protein 1 (AP-1) transcription factor complex, wherein the small molecule inhibitor is T-5224 (3-[5-(4-Cyclopentyloxy-2-hydroxybenzoyl)-2-[(3-oxo-1,2-benzoxazol-6-yl)methoxy phenyl]propanoic acid).
2 . The method of claim 1 , wherein the inhibitor is administered prior to a surgical procedure performed on the subject.
3 . The method of claim 1 , wherein the inhibitor is administered after a surgical procedure performed on the subject.
4 . The method of claim 1 , wherein the inhibitor is formulated in a particulate form.
5 . The method of claim 4 , wherein the particulate form is a PLGA microparticle.
6 . The method of claim 1 , wherein the inhibitor is administered in a drug delivery device.
7 . The method of claim 4 , wherein the drug delivery device is a biodegradable matrix.
8 . The method of claim 5 , wherein the matrix is a hydrogel.
9 . A method of treating a subject to reduce adhesion formation or to reduce already-formed adhesions, the method comprising:
administering topically to a surgical site or cavity of a subject in need thereof an effective dose of a small molecule inhibitor of the Activator Protein 1 (AP-1) transcription factor complex, wherein the small molecule inhibitor is T-5224 (3-[5-(4-Cyclopentyloxy-2-hydroxybenzoyl)-2-[(3-oxo-1,2-benzoxazol-6-yl)methoxy]phenyl]propanoic acid).
10 . A method of treating a subject to reduce adhesion formation or to reduce already-formed adhesions, the method comprising:
administering topically to the abdominal cavity of a subject in need thereof an effective dose of a small molecule inhibitor of the Activator Protein 1 (AP-1) transcription factor complex, wherein the small molecule inhibitor is T-5224 (3-[5-(4-Cyclopentyloxy-2-hydroxybenzoyl)-2-[(3-oxo-1,2-benzoxazol-6-yl)methoxy]phenyl]propanoic acid).